From Lab to Lot Release: Analytical readiness in centralized and decentralized cell and gene therapy manufacturing
04 Nov 2026
Cell Therapy Development
- FDA's new CAR-T CMC guidance and the Potency Assurance draft both push the burden back onto sponsors to justify their analytical strategy from first principles. Is the field actually ready for that, or are most programs still reverse-engineering their potency assays to fit what regulators approved last time?
- Release testing is still the field's biggest hidden bottleneck. What does your current lot release timeline actually look like, and where are the assays that are consistently holding up the clock between manufacturing and infusion?
- CAR-T, TIL, MSC, and gene-modified products each demand a completely different analytical story. How are organizations managing that complexity without building an entirely separate validation package for every platform?
- Comparability is the industry's shared unsolved problem. When a program moves sites, which part of the analytical package breaks first, and who is actually setting the standard for what "equivalent" means across centralized and decentralized models?
- The patient is in the bed, the product is in the bag, and the release result is borderline. How are teams building the decision frameworks to handle that moment before it happens?